Trending News Today: FDA Green Lights Late-Stage Trial for Non-Opioid Painkiller

Top news of the day from across the health care landscape.

Pharmaceutical company PainReform has received approval from the FDA to begin late-stage clinical trials for a non-opiate pain relief drug, Reuters reported. According to the article, two phase 3 trials will investigate the product PRF-110, which prolongs the action of ropivacaine, a local analgesic, and will focus on post-operative pain relief in soft and hard tissue. In an earlier study, PRF-110 relieved pain for up to 72 hours, which is 10 times longer than the standard of care, the article reported.

A new study found that women who work long hours may be at an increased risk for diabetes, the New York Times reported. According to the article, researchers studied 7065 workers following their work hours and health over an average of 12 years, and recorded diabetes diagnoses beginning 2 years after the participants were enrolled. Compared with women who worked 35 and 40 hours a week, those who worked 45 hours or more had a 51% increased risk of diabetes, according to the study’s results.

On Tuesday, Pfizer Inc said it was delaying its drug price hikes that went into effect on July 1 after discussions with President Donald Trump, Reuters reported. According to the article, Pfizer said that it would defer price increases until the end of the year or until the president’s drug pricing blueprint goes into effect. Pfizer plans to return drug prices to their pre-July 1 levels as soon as possible, the article reported.